Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product

June 4, 2024

https://www.globenewswire.com/news-release/2024/06/04/2892922/15991/en/Amicus-Therapeutics-Receives-Prix-Galien-U-K-Award-for-Pombiliti-cipaglucosidase-alfa-Opfolda-miglustat-as-Best-Pharmaceutical-Product.html

PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the Galien Foundation has awarded the 2024 Prix Galien U.K. Award for Best Pharmaceutical Product to Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat). The prestigious Prix Galien is awarded to companies recognized for their outstanding advances in the discovery and development of innovative products that improve the overall human condition, and is regarded among the highest accolades for biopharmaceutical and medical technology research.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.